Total Marrow and Lymphoid Irradiation and Chemotherapy before Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Lymphocytic or Myelogenous Leukemia

Inclusion Criteria

• Participant has the ability and the willingness to sign the informed consent document (for adults only, for participants with mild cognitive abilities may use a legally authorized representative)
• Documented (signed) informed consent; the patient, family member and transplant staff physician (physician, nurse, and social worker) meet at least once prior to starting the transplant procedure; during this meeting all pertinent information with respect to risks and benefits to donor and recipient will be presented; alternative treatment modalities will be discussed; the risks are explained in detail in the enclosed consent forms
• Age: >= 16 years
• Karnofsky performance status >= 70% =< 2
• Acute lymphocytic leukemia or acute myelogenous leukemia who are not in first remission or second remission i.e. after failing induction therapy, or in relapse or beyond second remission; (prior therapy with VP-16 and Cytoxan is allowed)
• All candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR) identical siblings who is willing to donate bone marrow or primed blood stem cells or a 10/10 allele matched unrelated donor; a single allele mismatch at A, B, C, DR or DQ and a killer immunoglobulin-like receptor (KIR) mismatch at C will be allowed; all ABO blood group combinations of the donor/recipient are acceptable since even major ABO compatibilities can be dealt with by various techniques (Red cell exchange or plasma exchange)
• The time from the end last induction, re-induction, or consolidation regimen should be greater than or equal to 14 days from planned start of study treatment; Note: Chemotherapy given within 14 days of planned study enrollment for the purpose of controlling counts is permitted
• Total bilirubin =< 1.5 x upper limit of normal (ULN) OR 3 x ULN for Gilbert’s disease
• Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) =< 5 x ULN
• Measured creatinine clearance >= 80 ml/min per 24 hour urine collection OR serum creatinine =< 1.3 mg/dL
• Women of child bearing potential only: Negative urine or serum pregnancy test
• Pulmonary function tests: Forced expiratory volume in one second (FEV1) and carbon monoxide diffusion capacity (DLCO) (adjusted for Hb) >= 50% adjusted of predicted normal value
• Echocardiogram (ECHO) or multi gated acquisition scan (MUGA): ejection fraction of >= 50% AND no finding of abnormal wall motion (i.e. report does not indicate that wall motion is “abnormal” or “altered”)
• Electrocardiogram (EKG) showing no ischemic changes and no abnormal rhythm
• Agreement of men AND women-of-child-bearing-potential to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
• Agreement to enter companion IRB protocol 17222
• DONOR ELIGIBILITY: Donor evaluation and eligibility will be assessed as per current City of Hope standard operating procedure (SOP)

Exclusion Criteria

• Prior autologous or allogeneic hematopoietic stem cell
• Prior radiation therapy that would exclude the use of TMLI
• Use of gemtuzumab ozogamicin (mylotarg) or inotuzumab ozogamicin (besponsa) within 6 months prior to transplantation
• Plans during the trial to receive any other (non-trial) investigational agents, or concurrent biological, chemotherapy, or radiation therapy; (chemotherapy for white blood count control is permitted)
• Uncontrolled illness including ongoing or active infection
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to etoposide
• Patients with other active malignancies are ineligible for this study, other than localized malignancies
• Patients with psychological or medical condition that patient's physician deems unacceptable to proceed to allogeneic hematopoietic stem cell transplantation
• Women who are planning to become pregnant or breast feed during the trial
• Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study